Coexisting NRAS and BRAF mutations in primary familial melanomas with specific CDKN2A germline alterations.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

22 citing papers in PubMed, 36 citations in OpenAlex.

1. Clinical features and response to systemic therapy in NRAS-mutant Chinese melanoma patients.Journal of cancer research and clinical oncology · 2023
   Article
2. Considerations for Germline Testing in Melanoma: Updates in Behavioral Change and Pancreatic Surveillance for Carriers ofFrontiers in oncology · 2022
   Review
3. Scientific and clinical implications of genetic and cellular heterogeneity in uveal melanoma.Molecular biomedicine · 2021
   Review
4. The Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape.Frontiers in molecular biosciences · 2020
   Review
5. Variation in Cutaneous Patterns of Melanomagenesis According to Germline CDKN2A/CDK4 Status in Melanoma-Prone Families.The Journal of investigative dermatology · 2020
   Article
6. A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases.Translational oncology · 2019
   Article
7. Interplay between small and long non-coding RNAs in cutaneous melanoma: a complex jigsaw puzzle with missing pieces.Molecular oncology · 2019
   Review
8. Improvement of Genetic Testing for Cutaneous Melanoma in Countries With Low to Moderate Incidence: The Rule of 2 vs the Rule of 3.JAMA dermatology · 2017
   Article
9. Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.Genetics in medicine : official journal of the American College of Medical Genetics · 2017
   Article
10. Melanoma management · 2016
    Review
11. Phytochemicals for the Management of Melanoma.Mini reviews in medicinal chemistry · 2016
    Review
12. Histologic features of melanoma associated with CDKN2A genotype.Journal of the American Academy of Dermatology · 2015
    Article
13. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy.Cancer cell · 2014
    Article
14. Somatic BRAF and NRAS mutations in familial melanomas with known germline CDKN2A status: a GenoMEL study.The Journal of investigative dermatology · 2014
    Article
15. NRAS mutant melanoma: biological behavior and future strategies for therapeutic management.Oncogene · 2013
    Review
16. Melanoma: from melanocyte to genetic alterations and clinical options.Scientifica · 2013
    Review
17. NRAS mutation status is an independent prognostic factor in metastatic melanoma.Cancer · 2012
    Article
18. A brief history of melanoma: from mummies to mutations.Melanoma research · 2012
    Review
19. Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma.Biochemical pharmacology · 2011
    Review
20. Tumor heterogeneity and strategies to overcome kinase inhibitor resistance in cancer: lessons from melanoma.Expert opinion on investigational drugs · 2011
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

8 authors at 3 institutions in 3 countries.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as